Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects

Trial Profile

Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Everolimus; Sirolimus
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Apr 2017 New trial record
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top